Crystal structures of vertebrate dihydropyrimidinase and complexes from Tetraodon nigroviridis with lysine carbamylation: metal and structural requirements for post-translational modification and function.

J Biol Chem

From the Life Science Group, Scientific Research Division, National Synchrotron Radiation Research Center, Hsinchu 30076, Taiwan,; the Department of Physics, National Tsing Hua University, Hsinchu 30043, Taiwan, and; the Institute of Biotechnology and; University Center for Bioscience and Biotechnology, National Cheng Kung University, 1 University Road, Tainan City 701, Taiwan. Electronic address:

Published: October 2013

Lysine carbamylation, a post-translational modification, facilitates metal coordination for specific enzymatic activities. We have determined structures of the vertebrate dihydropyrimidinase from Tetraodon nigroviridis (TnDhp) in various states: the apoenzyme as well as two forms of the holoenzyme with one and two metals at the catalytic site. The essential active-site structural requirements have been identified for the possible existence of four metal-mediated stages of lysine carbamylation. Only one metal is sufficient for stabilizing lysine carbamylation; however, the post-translational lysine carbamylation facilitates additional metal coordination for the regulation of specific enzymatic activities through controlling the conformations of two dynamic loops, Ala(69)-Arg(74) and Met(158)-Met(165), located in the tunnel for the substrate entrance. The substrate/product tunnel is in the "open form" in the apo-TnDhp, in the "intermediate state" in the monometal TnDhp, and in the "closed form" in the dimetal TnDhp structure, respectively. Structural comparison also suggests that the C-terminal tail plays a role in the enzymatic function through interactions with the Ala(69)-Arg(74) dynamic loop. In addition, the structures of the dimetal TnDhp in complexes with hydantoin, N-carbamyl-β-alanine, and N-carbamyl-β-amino isobutyrate as well as apo-TnDhp in complex with a product analog, N-(2-acetamido)-iminodiacetic acid, have been determined. These structural results illustrate how a protein exploits unique lysines and the metal distribution to accomplish lysine carbamylation as well as subsequent enzymatic functions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798535PMC
http://dx.doi.org/10.1074/jbc.M113.496778DOI Listing

Publication Analysis

Top Keywords

lysine carbamylation
24
structures vertebrate
8
vertebrate dihydropyrimidinase
8
tetraodon nigroviridis
8
carbamylation metal
8
structural requirements
8
post-translational modification
8
carbamylation post-translational
8
metal coordination
8
specific enzymatic
8

Similar Publications

Cross-reactivity of anti-modified protein antibodies in rheumatoid arthritis.

Clin Exp Rheumatol

December 2024

Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, and Clinical Institute of Inflammation and Immunology (CIII), Frontiers Science Centre for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

This review comprehensively discusses the cross-reactivity of autoantibodies against modified proteins (AMPAs), the hallmark of rheumatoid arthritis (RA). We found that regardless of tissue sources, subtypes, or isotypes of B cells, AMPAs show high cross-reactivity within and across antigens undergoing citrullination, carbamylation, lysine-acetylation or ornithine-acetylation. The cross-reactive patterns of AMPAs display clonal and individual heterogeneity.

View Article and Find Full Text PDF

The presence of anti-citrullinated peptide/protein antibodies (ACPAs), anti-carbamylated peptide/protein antibodies (anti-CarPs), and anti-acetylated peptide/protein antibodies (AAPAs), collectively termed as anti-modified peptide/protein antibodies (AMPAs), is a hallmark of rheumatoid arthritis. These autoantibodies play a crucial role in the complex autoimmune responses observed in patients. Understanding the interplay between them is essential for early diagnosis and effective management of the disease.

View Article and Find Full Text PDF

Background:  Chronic kidney disease (CKD) is a progressive, irreversible, and incurable condition characterized by high morbidity and mortality, affecting approximately one-tenth of the global population. Rise of urea-derived cyanate levels in CKD patients, severalfold higher in comparison to those found in healthy individuals, leads to an increased rate of carbamylation of lysine residues of proteins and peptides. This posttranslational modification plays an important role in the progression of kidney failure but also in the onset of CKD-related complications, including previously reported coagulopathies.

View Article and Find Full Text PDF
Article Synopsis
  • Protein carbamylation, influenced mainly by urea, has a negative impact on clinical outcomes for patients with chronic kidney disease (CKD), with key biomarkers being carbamylated albumin (C-Alb) and homocitrulline (HCit).
  • In a study involving 1,632 CKD participants, both C-Alb and HCit were measured together to assess their prognostic value for death and end-stage kidney disease (ESKD).
  • The findings showed that both biomarkers were significantly associated with increased risks for death and ESKD, and they had comparable prognostic capabilities in statistical models.
View Article and Find Full Text PDF

Anti-carbamylated protein antibodies drive AEC II toward a profibrotic phenotype by interacting with carbamylated TLR5.

Rheumatology (Oxford)

October 2024

Department of Rheumatology and Immunology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.

Objectives: This study looked at the role of anti-carbamylated protein (anti-CarP) antibodies in contributing to lung fibrosis in CTD-associated interstitial lung disease (ILD) in an autoantigen-dependent manner.

Methods: ELISA was used to test serum samples, including 89 from the CTD-ILD group and 170 from the non-CTD-ILD group, for anti-CarP levels. Male C57BL/6 mice were used for the pulmonary fibrosis model and anti-CarP treatment in vivo (n = 5) and patient serum-derived or commercialized anti-CarP was used for cell treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!